INOVIO PHARMACEUTICALS INC's ticker is INO and the CUSIP is 45773H201. A total of 128 filers reported holding INOVIO PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1 | -97.6% | 1,626 | -96.8% | 0.00% | – |
| Q1 2023 | $42 | -80.4% | 50,726 | -63.0% | 0.00% | – |
| Q4 2022 | $214 | -99.9% | 137,026 | +0.2% | 0.00% | – |
| Q3 2022 | $236,000 | 0.0% | 136,763 | +0.3% | 0.00% | – |
| Q2 2022 | $236,000 | -51.9% | 136,411 | -0.2% | 0.00% | -100.0% |
| Q1 2022 | $491,000 | -28.0% | 136,730 | +0.1% | 0.00% | 0.0% |
| Q4 2021 | $682,000 | -30.5% | 136,599 | -0.3% | 0.00% | 0.0% |
| Q3 2021 | $981,000 | -40.8% | 137,031 | -23.3% | 0.00% | -50.0% |
| Q2 2021 | $1,656,000 | +16.5% | 178,593 | +16.7% | 0.00% | 0.0% |
| Q1 2021 | $1,421,000 | +13.1% | 153,100 | +7.9% | 0.00% | +100.0% |
| Q4 2020 | $1,256,000 | -23.7% | 141,900 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $1,646,000 | -53.7% | 141,900 | +7.7% | 0.00% | -60.0% |
| Q2 2020 | $3,552,000 | +635.4% | 131,800 | +103.1% | 0.01% | +400.0% |
| Q1 2020 | $483,000 | +125.7% | 64,900 | 0.0% | 0.00% | – |
| Q4 2019 | $214,000 | +60.9% | 64,900 | 0.0% | 0.00% | – |
| Q3 2019 | $133,000 | -30.4% | 64,900 | 0.0% | 0.00% | – |
| Q2 2019 | $191,000 | -21.1% | 64,900 | 0.0% | 0.00% | – |
| Q1 2019 | $242,000 | -6.9% | 64,900 | 0.0% | 0.00% | – |
| Q4 2018 | $260,000 | -44.2% | 64,900 | -22.6% | 0.00% | -100.0% |
| Q3 2018 | $466,000 | +25.3% | 83,800 | -11.6% | 0.00% | – |
| Q2 2018 | $372,000 | -46.0% | 94,800 | -35.2% | 0.00% | -100.0% |
| Q1 2018 | $689,000 | +30.5% | 146,243 | +14.3% | 0.00% | 0.0% |
| Q4 2017 | $528,000 | -34.9% | 127,943 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $811,000 | -5.4% | 127,943 | +17.1% | 0.00% | 0.0% |
| Q2 2017 | $857,000 | -47.9% | 109,271 | -56.0% | 0.00% | -50.0% |
| Q1 2017 | $1,645,000 | +2.9% | 248,483 | +7.8% | 0.00% | 0.0% |
| Q4 2016 | $1,599,000 | -25.6% | 230,458 | 0.0% | 0.00% | -33.3% |
| Q3 2016 | $2,148,000 | +33.7% | 230,458 | +32.6% | 0.00% | +50.0% |
| Q2 2016 | $1,606,000 | -42.0% | 173,827 | -45.3% | 0.00% | -50.0% |
| Q1 2016 | $2,769,000 | +3.6% | 317,890 | -20.0% | 0.00% | 0.0% |
| Q4 2015 | $2,672,000 | +16.3% | 397,556 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $2,298,000 | -26.5% | 397,556 | +3.8% | 0.00% | -20.0% |
| Q2 2015 | $3,125,000 | +99.9% | 382,921 | +99.9% | 0.01% | +150.0% |
| Q1 2015 | $1,563,000 | +17.6% | 191,558 | +32.3% | 0.00% | 0.0% |
| Q4 2014 | $1,329,000 | +112.3% | 144,758 | +127.9% | 0.00% | +100.0% |
| Q3 2014 | $626,000 | – | 63,523 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON ASSOCIATES LP | 784,679 | $643,437 | 0.10% |
| Green Alpha Advisors, LLC | 146,300 | $119,966 | 0.08% |
| Virtus ETF Advisers LLC | 54,106 | $44,367 | 0.02% |
| Cedar Brook Financial Partners, LLC | 104,881 | $86,002 | 0.02% |
| PROFUND ADVISORS LLC | 418,749 | $343,374 | 0.02% |
| Arlington Capital Management, Inc. | 27,735 | $22,743 | 0.02% |
| Hennion & Walsh Asset Management, Inc. | 382,158 | $313 | 0.02% |
| Rafferty Asset Management, LLC | 2,647,927 | $2,171,300 | 0.02% |
| Brainard Capital Management LLC | 16,666 | $13,666 | 0.01% |
| Beck Bode, LLC | 41,218 | $33,799 | 0.01% |